Prevalence of NRAS, PTEN and AKT1 gene mutations in the central nervous system metastases of non-small cell lung cancer

AbstractSomatic mutations inNRAS, PTEN andAKT1 genes are rarely (~1%) reported in primary NSCLC, but their role in carcinogenesis have been proven. Therefore, we assessed the frequency of them in 145 FFPE tissue samples from CNS metastases of NSCLC using the real-time PCR technique. We identified four (twoNRAS and singleAKT1 andPTEN) mutations in CNS metastases of NSCLC. All mutations were observed in current male smokers (4% out of the male group; 4/100 and 4.25% out of smokers; 4/94). Three mutations have been detected in patients with SqCC (10.3% out of SqCC patients; 3/29), and only one mutation in theNRAS gene —in a patient with adenocarcinoma (1.25% out of AC patients; 1/80). The examined genes were mutually exclusive in terms of molecular background inKRAS; EGFR; DDR2; PIK3CA; HER2 andMEK1 genes that were evaluated in our previous studies. The OS of the patients who harboredNRAS, AKT1 andPTEN mutations was 10.1, 12.1, 7.3 and 4 months, respectively (vs 13.5 months of the studied group). Our results suggest that the presence ofNRAS, PTEN andAKT1 gene mutations may have an influence on the occurrence of CNS metastases in patients with SqCC.
Source: Brain Tumor Pathology - Category: Neurology Source Type: research